Business

MASS. MOVERS

Drug delays cancer’s spread, trials show

Woburn-based ArQule Inc. rallied 12 percent, the most since July 2010. ArQule, a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics, reported that its tivantinib product delayed the progression of cancer in a phase two study of 107 patients. All had liver cancer and had been treated previously. Tivantinib (also known as ARQ 197) is designed to block the activity of a molecule known as c-Met that plays multiple roles in cancer. It is ArQule’s lead product.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com